Summary of public comments received on the draft screening assessment and risk management scope for 2H-1-Benzopyran-2-one, 7-(diethylamino)-4-methyl- (Coumarin 1)
Comments on the Draft Screening Assessment and Risk Management Scope for 2H-1-Benzopyran-2-one, 7-(diethylamino)-4-methyl- (Coumarin 1), assessed under the Chemicals Management Plan (CMP), were submitted by Canadian Consumer Specialty Products Association and Pratt & Whitney Canada.
Summarized public comments and responses are provided below, organized by topic:
Sources and uses
Comment summary 1: Additional product use and concentration information was provided for coumarin 1. Stakeholders also remain available should input be required in the finalization of the assessment.
Response 1: Additional use and concentration information submitted was considered and non-confidential information was incorporated, as appropriate, into the final screening assessment.
Risk management
Comment summary 2: The submitter is seeking confirmation that uses of coumarin 1 in non-cosmetic product formulations are not of concern and will be exempted from risk management.
Response 2: The Government of Canada’s proposed risk management activities focus on minimizing the risks identified in the risk assessment based on available information. These include measures to reduce dermal exposure of the Canadian population to coumarin 1 from specialty body makeup and temporary gel hair dye, by describing coumarin 1 as a prohibited or restricted ingredient on the Health Canada Cosmetic Ingredient Hotlist. The Hotlist is used to communicate that certain substances may not be compliant with requirements of the Food and Drugs Act or provisions of the Cosmetic Regulations. More information on the Hotlist consultation process can be found here.
Comment summary 3: The submitter wishes to be kept informed of any future developments and discussions with the stakeholders on risk management actions concerning coumarin 1.
Response 3: The Government of Canada is committed to consulting with all affected stakeholders and the public. Consultations continue throughout risk management tool development and implementation. Stakeholder input on information gaps, technical considerations and socio-economic impacts can help inform the decisions made to manage risks for a CEPA-toxic substance.